Congress Presses Commerce to Mandate DNA Synthesis Screening as White House Misses Its Own Deadline

The voluntary system that currently governs who can order made-to-order DNA sequences has a compliance gap Washington is not moving fast enough to close, and a growing coalition of scientists, AI companies, and biosecurity specialists wants Congress to act before the executive branch gets around to it.

The Biosecurity Modernization and Innovation Act of 2026, introduced January 29 in the Senate as S. 3741, would require the Commerce Department to issue binding regulations for nucleic acid synthesis security. According to the bill text reviewed at Congress.gov, the legislation covers any person who synthesizes and sells synthetic nucleic acids to buyers in the United States, as well as vendors of benchtop synthesizers. Federally funded researchers would be prohibited from purchasing synthesis products from providers that don't comply.

The bill is a bipartisan vehicle. It's also a direct acknowledgment that the current arrangement is not holding. The International Gene Synthesis Consortium, the industry's own self-regulatory body, has developed what it describes as a common protocol for screening both purchase sequences and customers. But industry self-certification, by definition, covers only those who opt in. The bill's sense-of-Congress section states plainly that gene synthesis technology is becoming more accessible and that bad actors may exploit that to develop new pathogens.

The legislative push arrives against a backdrop of executive inaction. An Executive Order issued in May 2025 directed the Office of Science and Technology Policy to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening within 90 days. According to a Congressional Research Service analysis reviewed at CRS.gov, as of July 2026 the administration had not replaced that framework despite its own deadline. That's a confidence-lowering data point for anyone tracking whether the executive branch has biosecurity governance under control.

The pressure from outside government is real. In June 2026, a coalition of life sciences researchers, AI companies, and biotechnology developers sent an open letter to Congress calling for mandatory screening of synthetic nucleic acid orders and the equipment used to make them, according to a CRS report updated in August 2026. The Belfer Center at Harvard assessed, in an analysis posted roughly two weeks ago, that the U.S. federal framework "remains fragmented, lacking a single AI-biosecurity regulator" and no sweeping federal statute on AI use and biosecurity has been enacted as of August 2026.

The dual-use tension here is not hypothetical. AI tools already design DNA sequences, characterize proteins, and run experiments through autonomous laboratory platforms. The concern, low-to-moderate confidence at this stage, is that the combination of AI-assisted design and accessible synthesis equipment could lower the expertise floor enough to bring pathogen engineering within reach of actors who couldn't manage it before. The CRS analysis notes that some researchers argue AI could be repurposed to produce biological compounds of concern, though the evidentiary record for specific incidents remains thin in open-source channels.

The Nuclear Threat Initiative endorsed the bill in April 2026, citing its proposal to establish an innovation hub inside the government that brings together commercial, academic, and government stakeholders to embed biosecurity by design. The NTI called the bill's approach to streamlining federal oversight of dual-use bioscience "core pillars of a comprehensive national biosafety and biosecurity strategy."

S. 3741 was referred to the Senate Commerce, Science, and Transportation Committee after introduction. There's no public committee markup scheduled as of this writing. The House has a companion vehicle, H.R. 3029, the Nucleic Acid Standards for Biosecurity Act. Whether either chamber moves before the 119th Congress expires is the operative question. The missed OSTP deadline suggests the executive won't fill the gap on its own schedule.

Sources cited:
- S. 3741 bill text, Congress.gov (https://www.congress.gov/bill/119th-congress/senate-bill/3741/text)
- Congressional Research Service, Addressing Biosecurity Concerns of AI Models (updated August 2026), EveryCRSReport (https://www.everycrsreport.com/files/2026-08-03_IF13269_08358480395929b0108af79e6b4d2998a5f4d4f0.html)
- CRS report via Congress.gov, Artificial Intelligence and Biosecurity Issues (https://www.congress.gov/crs-product/IF13269)
- Belfer Center, The Dual-Use Frontier of AI-Enabled Biotechnology (https://www.belfercenter.org/research-analysis/dual-use-frontier-ai-enabled-biotechnology-civilian-opportunities-national)
- NTI, NTI Endorses Biosecurity Modernization and Innovation Act of 2026 (https://www.nti.org/news/nti-endorses-biosecurity-modernization-and-innovation-act-of-2026/)
- Legis1, AI and Biosecurity Risks Outpace Federal Regulatory Response (https://legis1.com/news/ai-biosecurity-risks-and-outpace-federal)